Mianserin (Bolvidon, Norval, Tolvon,ORG GB-94 HCl,Mianserin hydrochloride) is an potent antagonist of H1 histamine receptor and 5-HT serotonin receptors, used for the treatment of depression.
More Information Supplier PageMizoribine is an imidazole nucleoside and an immunosuppressant that inhibits HCV RNA replication with IC50 of ~ 100 μM for anti-HCV activity. Mizoribine is a selective inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase. Mizoribine also inhibits SARS-CoV.
More Information Supplier PageMosapride Citrate (TAK-370, AS-4370, Gasmotin) is a gastroprokinetic agent that acts as a selective 5HT4 agonist.
More Information Supplier PageNafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. Nafamostat mesylate blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. Nafamostat Mesilate attenuates inflammation and apoptosis.
More Information Supplier PageNaftopidil DiHCl (Flivas, KT-611, Avishot,BM-15275) is a selective 5-HT1A and α1-adrenergic receptor antagonist with IC50 of 0.1 μM and 0.2 μM, respectively.
More Information Supplier PageDrospirenone (ZK 3059) is a synthetic progestin that is an analog to spironolactone.
More Information Supplier PageDrospirenone (ZK 3059) is a synthetic progestin that is an analog to spironolactone.
More Information Supplier PageRuxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
More Information Supplier PageRuxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
More Information Supplier PageRuxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
More Information Supplier Page
